Jesper Høiland is President of Novo Nordisk Inc. USA and Executive Vice President Novo Nordisk A/S. He joined the region in 2013 after spending nearly a decade leading the global company’s International Operations in Switzerland, which constitutes 150 countries with the “emerging markets” segments and 40 Novo Nordisk affiliates.
Recent research conducted in Houston is beginning to reveal how far-reaching the risk of diabetes really is and how even people who may not consider themselves vulnerable may be on a path to developing the disease.
